GlassScriptPhysician profile
James F Flaherty
NPI 1518071513
$9,791.21
in general payments reported to CMS, 2019-2025
9 companies · $86.99 in 2025
The $86.99 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.16 · 2020: $17.29 · 2021: $11.26 · 2022: $5,587 · 2023: $3,239 · 2024: $829 · 2025: $86.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,175 · Travel and Lodging: $808 · Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,174.70 |
| Travel and Lodging | $808.20 |
| Food and Beverage | $171.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,530.75 | 2022-2024 | Davinci Xi, Da Vinci Surgical System |
| Takeda Pharmaceuticals U.S.A., INC. | $73.52 | 2021-2023 | Gattex |
| Merck Sharp & Dohme LLC | $59.20 | 2025 | Keytruda |
| Tela Bio, INC. | $27.79 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $26.79 | 2022 | |
| Shire North American Group INC | $21.16 | 2019 | |
| Kerecis Limited | $17.77 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Nestle Healthcare Nutrition INC. | $17.29 | 2020 | |
| Conmed Corporation | $16.94 | 2024 | Airseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.